spacer
home > ebr > summer 2002 > early phase clinical trials of biopharmaceuticals
PUBLICATIONS
European Biopharmaceutical Review

Early Phase Clinical Trials of Biopharmaceuticals

New pharmacological treatments are currently evaluated in humans through clinical pharmacology trials in gradually rising numbers of healthy and patient volunteers. Sufficient information about safety, pharmacokinetic parameters and ideally efficacy, has to be gained before confirmatory therapeutic studies can be justified and accepted by the regulatory agencies, ethics committees, patients and clinicians. Clinical trials of new putative therapeutic agents performed in healthy volunteers (human pharmacology studies) are not considered mandatory, but in practice are frequently requested and conducted. With the exception of cytotoxic compounds, these studies are useful in bridging the knowledge gap between animal and patients during these challenging exploratory phases. The information obtained by pharmacokinetic parameters and safety/tolerability profile of different dose levels will be made available to investigators and clinicians for a rational management of clinical situations in patients. Biopharmaceuticals differ in various ways from the typical chemical entity and some alternative approaches to both the preclinical and clinical evaluation must be considered during the development of this varied class of products. It is acknowledged that a flexible, case-by-case approach is particularly appropriate for biotechnology-derived pharmaceuticals. The main aim of this article is to give a brief introductory overview of the key points to be considered before and during the initial evaluation of biopharmaceuticals in humans. Emphasis will be placed on the general principles applied by investigators to minimise mistakes occurring during the clinical development phase.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Salvatore Febbraro, Medical Director at Simbec Research Ltd

Dr Salvatore Febbraro is Medical Director and Principal Investigator at Simbec Research, a CRO specialising in early phase drug development. Salvatore is a medical doctor and he graduated from the University of Naples.
Prior to joining the pharmaceutical industry he worked in several teaching and district hospitals, both in Italy and the UK. In the last 10 years, Salvatore has worked for three large CROs and one major pharmaceutical company. In these positions, he was responsible for the medical management of several hundred human pharmacology and exploratory therapeutic trials of novel chemical entities and biopharmaceuticals in a broad range of therapeutic areas.

spacer
Dr Salvatore Febbraro
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers
 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement